Drug intelligence / Profile preview

Etronex Gel

Development stage: Unknown
Lead developer: MetaneX Life Science
Modality: Small Molecules
Administration: Topical

Overview

Etronex Gel is a branded generic topical pain relief formulation marketed by MetaneX Life Science. It is designed to alleviate localized pain, swelling, and inflammation associated with musculoskeletal disorders, joint pain, sprains, strains, and arthritic conditions. The gel formulation typically combines the selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib with counterirritants such as methyl salicylate and menthol, alongside linseed oil to enhance dermal absorption and provide additional anti-inflammatory benefits. Applied topically, it delivers rapid local relief with minimal systemic side effects.

Brand names: Etronex Gel

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Etronex Gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Etronex Gel.

Explore the full profile